Cellular Biomedicine completes enrollment in ReJoin Phase IIb clinical trial Cellular Biomedicine has completed the patient enrollment required for its Phase IIb trial to further evaluate the safety and efficacy of their proprietary adipose-derived mesenchymal precursor cell-based therapy ReJoin for Knee Osteoarthritis. The Phase I/IIa clinical trial for this therapy was completed in 4Q13. The primary endpoints for this trial are knee-related pain, stiffness and function.
Cellular Biomedicine announces positive Phase I results from CAR-T CD30 trial Cellular Biomedicine Group announced encouraging clinical data from its Chimeric Antigen Receptor, or CAR-T, CD30-positive Hodgkin's lymphoma immuno-oncology clinical development program. The results of this trial to date demonstrated that five out of seven patients responded to the treatment. CD30-directed CAR-T cell therapy was demonstrated in this trial to be safe, feasible and efficient. This trial was a Phase I, open-label trial whereby enrolled patients received escalating doses of autologous T cells transduced with a CD30-directed chimeric antigen receptor moiety for a consecutive 3-5 days. The level of CAR transgenes in peripheral blood and biopsied tumor tissues were measured periodically according to assigned protocol by Quantitative PCR.